We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    LAANTERN
Previous Study | Return to List | Next Study

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN)

This study is currently recruiting participants.
Verified August 2017 by Monteris Medical
Sponsor:
ClinicalTrials.gov Identifier:
NCT02392078
First Posted: March 18, 2015
Last Update Posted: October 3, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Monteris Medical
  Purpose
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 1300 procedures conducted at approximately 56 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 12 months to evaluate procedural success, local control failure rate, and QoL in up to 1,000 patients and up to 50 sites. Currently, the study has 162 subjects enrolled from 14 active sites

Condition Intervention
Metastatic Brain Tumor Primary Brain Tumor Device: NeuroBlate System

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry

Further study details as provided by Monteris Medical:

Primary Outcome Measures:
  • Procedural Success [ Time Frame: up to 12 months ]
  • Local control Failure Rate [ Time Frame: up to 12 months ]
  • Quality of Life [ Time Frame: up to 12 months ]

Secondary Outcome Measures:
  • Safety (Reportable adverse events) [ Time Frame: up to 12 months ]

Estimated Enrollment: 1000
Study Start Date: October 2015
Estimated Study Completion Date: September 2020
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who preferred management for soft tissue through interstitial irradiation or thermal therapy by the NeuroBlate® System, in the opinion of the treating physician
Criteria

Inclusion Criteria:

  1. Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  2. Patient who is to undergo thermal therapy by the NeuroBlate® System for treatment of their neurological disorder

Exclusion Criteria:

  1. Patient who is, or is expected to be inaccessible for follow-up
  2. Patient meets any exclusion criteria required by local law (e.g. age)
  3. Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator may prevent participation or otherwise render patient ineligibility for the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02392078


Contacts
Contact: Nissa Mollema 763-253-4710 nmollema@monteris.com
Contact: Aurelius Butler (763) 762-2715 ext 2715 abutler@monteris.com

Locations
United States, California
University of California, San Diego Recruiting
La Jolla, California, United States, 92093
Contact: Lara Rose    858-822-6575    ljrose@ucsd.edu   
Principal Investigator: Clark Chen, md         
United States, Connecticut
Yale University School of Medicine Recruiting
New Haven, Connecticut, United States, 06510
Contact: Judith Hess    203-737-6259    judith.hess@yale.edu   
Principal Investigator: Veronica Chiang, MD         
United States, Florida
Florida Hospital Recruiting
Orlando, Florida, United States, 32804
Contact: Karin Donaldson    407-303-2944    karin.donaldson@flhosp.org   
Principal Investigator: Melvin Field, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Cathy T Lauridsen    913-588-4573    clauridsen2@kumc.edu   
United States, Kentucky
University of Louisville Recruiting
Louisville, Kentucky, United States, 40208
Contact: Anna Williford    502-852-7402    aowill01@louisville.edu   
Principal Investigator: Joseph Neimat, MD         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Jeanine Wade    314-362-2940    jeanine.wade@wustl.edu   
Principal Investigator: Albert Kim, MD         
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10065
Contact: Alyson Hignight    212-746-1788    alh2031@med.cornell.edu   
Principal Investigator: Rohan Ramakrishna, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Kristy Averette    919-684-0380    kristy.l.johnson@duke.edu   
Principal Investigator: Peter Fecci, MD         
Wake Forest Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Wendy Jenkins    336-716-3842    wejenkin@wakehealth.edu   
Principal Investigator: Stephen Tatter, MD         
United States, Ohio
University Hospitals Cleveland Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Jennifer Fahrion    216-983-5169    jennifer.fahrion@uhhospitals.org   
Principal Investigator: Andrew Sloan, MD         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Dee Walick    216-445-8797    walickd@ccf.org   
Principal Investigator: Alireza Mohammadi, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Kara Pigott    215-503-9110    kara.pigott@jefferson.edu   
Principal Investigator: Kevin Judy, MD         
United States, Texas
MD Anderson Recruiting
Houston, Texas, United States, 77030
Contact: Patsy Concepcion    713-792-2933    pconcepcion@mdanderson.org   
Principal Investigator: Ganesh Rao, MD         
Canada, British Columbia
University of British Columbia Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Camille Hunt    604-875-4111 ext 62560    camille.hunt@ubc.ca   
Principal Investigator: Brian Toyota, MD         
Sponsors and Collaborators
Monteris Medical
Investigators
Principal Investigator: Eric Leuthardt, MD Washington University School of Medicine
  More Information

Responsible Party: Monteris Medical
ClinicalTrials.gov Identifier: NCT02392078     History of Changes
Other Study ID Numbers: LAANTERN
First Submitted: March 12, 2015
First Posted: March 18, 2015
Last Update Posted: October 3, 2017
Last Verified: August 2017

Keywords provided by Monteris Medical:
Procedural Success
Progression
Quality of Life

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases